Mode
Text Size
Log in / Sign up

Nomogram using baseline SUA and CD4+ count predicts hyperuricemia risk in people living with HIVWhat raises uric acid in HIV? New tool spots risk before symptoms start

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider using baseline SUA and CD4+ count to flag PLWH at higher hyperuricemia risk, pending external validation.

Researchers retrospectively analyzed people living with HIV (PLWH) treated at Hangzhou Xixi Hospital between July 2016 and December 2024 to identify independent risk factors for the time to hyperuricemia (HUA) and develop a risk-prediction model.

A total of 631 participants were randomly assigned to training (n=439) and validation (n=192) cohorts in a 7:3 ratio. Independent risk factors were identified via multivariable Cox regression; variables for the prediction model were selected via LASSO, and the model was visualized as a nomogram. Performance was assessed with time-dependent ROC, calibration curve, concordance index (C-index), and decision curve analysis (DCA). A generalized linear mixed model (GLMM) evaluated ART-regimen effects on serum uric acid (SUA) over time.

The final nomogram incorporated two factors: baseline SUA and baseline CD4+ T-cell count. AUC values for 1-, 3-, and 5-year HUA risk were 0.72, 0.74, and 0.75 in the training set and 0.66, 0.67, and 0.70 in the validation set. Calibration showed strong agreement between predicted and observed outcomes, and C-index and DCA supported nomogram performance. Prevalence of hypercholesterolemia and abnormal eGFR differed significantly between high- and low-risk groups. Compared with B/F/TAF regimens, SUA significantly decreased over time in PLWH receiving EFV-containing ART regimens.

Safety and tolerability outcomes were not reported. External validation was not reported; limitations include the retrospective, single-center design. Practice relevance is limited to early HUA-risk identification and should be interpreted cautiously until external validation.

Living with HIV often means managing many health details every single day. One hidden worry is high uric acid, which can strain your kidneys and joints over time. You want to know if your treatment plan puts you at risk before problems start.

Researchers looked back at records from 631 people living with HIV in China. They tracked uric acid levels and medication types over several years. The data showed that certain drug combinations led to lower uric acid levels compared to others. They also built a prediction model to identify high-risk patients.

This tool helps doctors spot risk early, but it has limits. The study only checked its own data, not data from other hospitals. It shows connections between factors, but it does not prove one thing causes another. External validation is not reported yet. More work is needed to be sure.

You should talk to your care team about these findings during your next visit. They might use this information to monitor your health more closely. It is a step toward better personalized care, even if more research is needed to confirm everything.

What this means for you:
A new tool helps predict high uric acid risk in HIV patients, though more research is needed to confirm results.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundThe aim of this study was to identify independent risk factors for the time to hyperuricemia (HUA) in PLWH and develop an HUA risk model based on a retrospective study in Hangzhou, China.MethodsPLWH treated at Hangzhou Xixi Hospital between July 2016 and December 2024 were randomly assigned to training and validation cohorts in a 7:3 ratio. Independent risk factors associated with the occurrence of HUA were identified using multivariable Cox regression analysis. Characteristic variables for constructing the HUA risk prediction model were selected through the least absolute shrinkage and selection operator (LASSO) method, and the model was visualized using a nomogram. The model’s performance was assessed through time-independent receiver operating characteristic (ROC) curve, calibration curve, concordance index (C-index), and decision curve analysis (DCA) to evaluate its discriminatory ability, calibration, and clinical applicability. A generalized linear mixed model (GLMM) was used to investigate the effects of different ART regimens on the SUA levels over time among PLWH.ResultsA total of 631 participants were included in this study, with 439 assigned to the training set and 192 to the validation set. The final model for predicting HUA risk in PLWH incorporated two factors: baseline serum uric acid (SUA) levels and baseline CD4+ T-cell count. The area under the ROC curve (AUC) values for 1-, 3-, and 5-year HUA risks were 0.72, 0.74, and 0.75 in the training set, and 0.66, 0.67, and 0.70 in the internal validation sample, respectively. The calibration curve demonstrated strong agreement between predicted and observed outcomes. Both the C-index and DCA confirmed the nomogram’s superior predictive performance. Furthermore, the prevalence of hypercholesterolemia and abnormal eGFR differed significantly between the defined high- and low-risk groups. Comparing with PLWH receiving the B/F/TAF regimens, there was a significant decrease in SUA values over time in PLWH receiving EFV-containing ART regimens.ConclusionsWe established and validated a HUA-specific nomogram for predicting the risk of HUA in PLWH. This model provides clinicians with a practical tool for the early-stage identification of PLWH at high risk of HUA, a capability that is highly significant for guiding clinical treatment.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.